To include your compound in the COVID-19 Resource Center, submit it here.

Mylan's Herceptin biosimilar gets FDA approval

FDA approved Ogivri trastuzumab-dkst (MYL-1401O, CANMab, Hertraz) from Mylan N.V. (NASDAQ:MYL; Tel Aviv:MYL), a biosimilar of cancer drug

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE